Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above.

Next Previous
X
Search
Trial Profile

A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms AReSVi 006; RSV OA=ADJ-006
  • Sponsors GlaxoSmithKline Biologicals; GSK

    • Most Recent Events

    • 08 Oct 2024 Results published in a GSK plc media release
    • 08 Oct 2024 According to a GSK plc media release, new data from AReSVi-006 trial will be presented today at the CHEST 2024 Annual Meeting, organised by the American College of Chest Physicians. In addition to the presentation at CHEST, the data will be submitted for scientific peer-reviewed publication and to regulators for review.
    • 07 Oct 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top